DEFA14A: Avid Bioservices Recommends Stockholders Vote FOR Acquisition by GHO Capital and Ampersand Capital

Avid Bioservices urges stockholders to vote in favor of the proposed acquisition by GHO Capital Partners and Ampersand Capital Partners at $12.50 per share.

Summary

• Avid Bioservices has commenced mailing definitive proxy materials to stockholders regarding its pending transaction with GHO Capital Partners and Ampersand Capital Partners.
• A special meeting is scheduled for January 30, 2025, for stockholders to vote on the transaction.
• The Avid Board of Directors unanimously recommends stockholders vote FOR the transaction.
• The transaction offers $12.50 per share in cash, representing a 13.8% premium to the closing share price on November 6, 2024.
• The offer represents a 63.8% premium to the closing price on June 4, 2024, prior to the initial proposal from GHO and Ampersand.
• The Board believes the transaction maximizes value for stockholders after a thorough process involving outreach to 24 potential buyers and five improvements to the offer.
• The Board considered industry-wide macroeconomic headwinds, the need for additional investments, and updated growth expectations in its decision.
• The transaction is viewed as de-risking Avid's future as a standalone company.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment regarding the proposed acquisition, emphasizing the benefits to stockholders and the thoroughness of the process. While acknowledging industry challenges, the overall tone is optimistic about the transaction's outcome.

Positives

• The all-cash consideration of $12.50 per share provides immediate and certain value to Avid stockholders.
• The transaction represents a significant premium over Avid's historical share prices.
• The Board conducted a robust process to maximize value, including engaging with multiple potential buyers.
• The transaction mitigates risks associated with Avid's future as a standalone company, including macroeconomic headwinds and the need for additional investments.

Negatives

• The document highlights concerns about industry-wide macroeconomic headwinds, including uncertainty around biotech funding and increasing competition.
• Avid requires additional investments to capitalize on its growth potential.
• The company's growth prospects were below its own previous guidance as well as analysts' consensus.

Risks

• The transaction is subject to regulatory approvals and stockholder approval.
• There is a risk of the deal not closing due to various factors, including failure to satisfy conditions or termination of the merger agreement.
• The announcement of the transaction could have adverse effects on the market price of Avid's common stock.
• The transaction could lead to disruption of management time and potential difficulties in retaining key personnel and maintaining relationships with customers and vendors.

Future Outlook

The document focuses on the proposed acquisition and does not provide specific forward-looking statements about Avid's future operations beyond the transaction.

Management Comments

• The Board of Directors unanimously recommends stockholders to vote FOR the transaction.
• The Board is confident that this robust process has led to the value maximizing outcome for stockholders.
• The Board determined that the transaction with GHO and Ampersand represented a value maximizing outcome for Avid stockholders, providing superior risk-adjusted value and certainty of execution.

Industry Context

The document mentions industry-wide macroeconomic headwinds, including uncertainty around biotech funding, increased volatility from political and global trade tensions, and increasing competition in the biologics manufacturing industry.

Comparison to Industry Standards

• The document does not provide specific comparisons to industry standards or benchmarks.
• The document focuses on the premium offered to Avid's stockholders and the process undertaken to maximize value.

Stakeholder Impact

• Stockholders are expected to receive significant cash value for their shares.
• The transaction could impact employees, customers, and other stakeholders, although the specific effects are not detailed in this document.

Next Steps

• Stockholders need to vote on the proposed transaction by January 30, 2025.
• The transaction is subject to regulatory approvals and satisfaction of other closing conditions.

Key Dates

Keywords

acquisition, merger, CDMO, GHO Capital Partners, Ampersand Capital Partners, Avid Bioservices, stockholders, proxy statement, transaction